Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 303 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: VIAject/Insulin Glargine Clear all
Completed Phase 3 Interventional Results available

A Study in Adults With Type 1 Diabetes

NCT01421147
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2963016, Lantus, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Hollywood, Florida • New Port Richey, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 2, 2026, 1:44 PM EDT
Completed No phase listed Observational

Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

NCT02843399
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
15,498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

NCT00418522
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Inhaled Insulin (Exubera)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 75 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

NCT01849289
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin Degludec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

NCT04605991
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY900014, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
30
States / cities
Concord, California • Escondido, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Mylan Insulin Glargine Study

NCT03376789
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
MYL-1501D product using manufacture process V, MYL-1501D product using manufacture process VI
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
38
States / cities
Fresno, California • Greenbrae, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT02273180
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, Humalog, Insulin glargine HOE901
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

NCT01336751
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

NCT06340854
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Fresno, California • Hawthorne, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 2, 2026, 1:44 PM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes mellitus Type 2 De-escalation treatment (DET)
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 1 Diabetes Mellitus

NCT01481779
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glargine, LY2605541, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Concord, California • Escondido, California • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

NCT01654380
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
LY2605541, Insulin glargine
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes

NCT00348374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Exubera
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 2, 2026, 1:44 PM EDT
Terminated Not applicable Interventional Results available

Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin

NCT03455985
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
Interventions
Discharge Order Set (DOS), Enhanced Standard Care (ESC)
Other
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 75 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

NCT00127634
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Sacramento, California • Walnut Creek, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 2, 2026, 1:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

NCT07076199
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin icodec, Insulin glargine, Insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
103
States / cities
Cullman, Alabama • Concord, California • Escondido, California + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

NCT00667732
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

NCT01582451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 2, 2026, 1:44 PM EDT
Terminated Phase 4 Interventional

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

NCT02189395
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH and regular insulin, glargine and humalog
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 2, 2026, 1:44 PM EDT
Completed Not applicable Interventional

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

NCT02930044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion
Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 2, 2026, 1:44 PM EDT